Advaxia Biologics

Advaxia Biologics is a private, revenue-generating CDMO focused on the development and manufacturing of adenovirus-based therapeutics and vaccines. The company leverages its state-of-the-art facility near Rome and a fully integrated service portfolio to support clients from preclinical stages through clinical supply, boasting a 100% batch approval rate. While its website emphasizes a services business model, the initial company data suggests an internal focus on immunology and oncology therapeutics, indicating a potential dual strategy of service provision and proprietary pipeline development, though the latter is not detailed publicly.

Specialized adenovirus vector platform for development and cGMP manufacturing of vaccines and biologics, with integrated capabilities in expression systems, process development, analytics, and production.

Advaxia competes in the CDMO space with large global players (Lonza, Catalent) and specialized viral vector CDMOs (Oxford Biomedica, Batavia Biosciences). Its differentiation lies in its specific focus on adenovirus, a 100% batch success claim, and integrated services from development to manufacturing. For proprietary therapies, it would compete with numerous biotech firms in immuno-oncology.